Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This research highlights the lack of clinical evidence linking GLP-1 agonists, commonly used in treating type 2 diabetes and obesity, to hair loss, despite theoretical concerns regarding potential hair health impacts.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

GLP-1 receptor agonists may help or harm hair health, needing more research.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

This study observed that dermatological and hair changes, like skin sagging and hair shedding, commonly occur early during weight loss with GLP-1 receptor agonists, highlighting the need for tailored dermatological care alongside treatment.

This meta-analysis found that GLP-1 receptor agonists are associated with a 40% increased risk of non-scarring alopecia, likely due to weight loss-induced micronutrient deficiency, with significant associations for telogen effluvium and androgenetic alopecia. However, some patients with central centrifugal cicatricial alopecia showed improvement.

This study found that GLP-1 receptor agonists are linked to a 40% increased risk of non-scarring alopecia in adults, mainly due to weight loss-induced micronutrient deficiencies, with semaglutide and tirzepatide showing the highest hair loss signals.

This study found that GLP-1 receptor agonists are linked to a significant 40% increased risk of non-scarring alopecia, which may result from weight loss-induced micronutrient deficiency.

This study provides a narrative review suggesting GLP-1 receptor agonists could optimize metabolic health before conception in women with PCOS, but not necessarily improve fertility outcomes, emphasizing individualized use and the need for further research to confirm their reproductive benefits and safety.

This narrative review explores current evidence on GLP-1 receptor agonists and hair-related conditions, noting reports of both hair regrowth and potential associations with telogen effluvium.

This study found that hair shedding occurs in seven out of ten users of GLP-1 receptor agonists in real-world settings, a much higher prevalence than in clinical trials, which affects treatment adherence, especially among women experiencing significant weight loss.

This review suggests weak associations between GLP-1 receptor agonists and increased reports of hair loss, particularly with semaglutide and tirzepatide, while cases of hair regrowth were also occasionally documented.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

This review discusses the dermatologic side effects and potential therapeutic benefits of GLP-1 receptor agonists, such as facial fat loss and wound healing, emphasizing the need for further research.

This editorial examines how GLP-1 receptor agonists, providing significant weight loss and cardiovascular benefits, can be integrated into a comprehensive obesity treatment alongside diet and lifestyle changes, but highlights the need for further guidance on their real-world application and multidisciplinary care.

This study suggests that among GLP-1 agonists, liraglutide and exenatide are linked to the highest rates of gastrointestinal issues, including potentially pancreatitis-related enzyme changes noted in animal models.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

This study reports conflicting evidence on whether GLP-1 receptor agonists are associated with various forms of alopecia, suggesting dermatology practitioners should consider monitoring and counseling patients using these medications.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

In this study, GLP-1 receptor agonists reduced BMI and improved metabolic and reproductive outcomes in women with PCOS, though the long-term effects remain unclear.

This literature review highlights a potential but uncertain link between GLP-1 receptor agonist therapy for type 2 diabetes and obesity and hair loss, with variations among different medications.